Lyra Therapeutics receives Nasdaq deficiency notice for equity below $2.5M minimum

Lyra Therapeutics, Inc.

Stockholders' equity as of June 30, 2025 was ~$1.6M, below the $2.5M continued listing requirement.
Company has 45 calendar days (until October 4, 2025) to submit a plan to regain compliance to Nasdaq.
If plan is accepted, Nasdaq may grant up to 180 additional calendar days to evidence compliance.
Failure to regain compliance could lead to delisting; Company may appeal to a Nasdaq Hearings Panel.
No immediate effect on listing or trading of common stock under symbol LYRA on Nasdaq Capital Market.

item 3.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-186437
form_type: 8-K
ticker: LYRA
cik: 0001327273
company_name: Lyra Therapeutics, Inc.
filed_at: 2025-08-22T23:59:59+00:00
discovered_at: 2026-05-14T18:02:43.686043+00:00
generated_at: 2026-05-17T10:31:31.871042+00:00
sec_items: ["3.01"]
event_type: regulatory
sentiment: negative
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-186437
json_url: https://secwatch.observer/filing/0001193125-25-186437.json
markdown_url: https://secwatch.observer/filing/0001193125-25-186437.md
text_url: https://secwatch.observer/filing/0001193125-25-186437.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1327273/000119312525186437/0001193125-25-186437-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1327273/000119312525186437/d931635d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-186437

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.